Stephens analyst Mason Carrico raised the firm’s price target on Myriad Genetics to $24 from $17 and keeps an Equal Weight rating on the shares after the company reported Q4 results that beat the firm’s and consensus expectations and gave FY23 revenue guidance whose mid-point was above the firm’s and consensus estimates into the quarter. The firm stays at Equal Weight, but says its "encouraged by the improvements that we are seeing."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MYGN:
- Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
- Myriad Genetics, Illumina expand partnership for HRD testing access
- Illumina and Myriad Genetics partner for HRD testing in the U.S.
- Myriad Genetics announce support for new screening practice guidlines from NSGC
- Myriad Genetics sees FY23 (40c)-(20c), consensus (30c)